Century Therapeutics Inc (NASDAQ: IPSC) on Friday, plunged -7.48% from the previous trading day, before settling in for the closing price of $1.07. Within the past 52 weeks, IPSC’s price has moved between $0.95 and $5.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -14.25% annually for the last half of the decade. The company achieved an average annual earnings per share of 30.64%. With a float of $34.81 million, this company’s outstanding shares have now reached $84.76 million.
In an organization with 165 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -404.17%, operating margin of -4925.59%, and the pretax margin is -4869.53%.
Century Therapeutics Inc (IPSC) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Century Therapeutics Inc is 59.06%, while institutional ownership is 31.02%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,267. In this transaction Chief Operations Officer of this company sold 1,033 shares at a rate of $1.23, taking the stock ownership to the 135,130 shares. Before that another transaction happened on Nov 04 ’24, when Company’s SVP Finance & Operations sold 283 for $1.23, making the entire transaction worth $347. This insider now owns 317,147 shares in total.
Century Therapeutics Inc (IPSC) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.64% per share during the next fiscal year.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Century Therapeutics Inc (IPSC) is currently performing well based on its current performance indicators. A quick ratio of 10.39 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 31.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.86, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.76 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.68 million. That was better than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.89%. Additionally, its Average True Range was 0.11.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 3.63%, which indicates a significant decrease from 16.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.97% in the past 14 days, which was lower than the 83.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2641, while its 200-day Moving Average is $2.1518. However, in the short run, Century Therapeutics Inc’s stock first resistance to watch stands at $1.0456. Second resistance stands at $1.1013. The third major resistance level sits at $1.1325. If the price goes on to break the first support level at $0.9587, it is likely to go to the next support level at $0.9275. The third support level lies at $0.8718 if the price breaches the second support level.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
Market capitalization of the company is 84.18 million based on 85,029K outstanding shares. Right now, sales total 2,240 K and income totals -136,670 K. The company made 790 K in profit during its latest quarter, and -31,230 K in sales during its previous quarter.
